Form 4 for CI Cigna
Accepted 2023-07-21 00:00:00 ET · period of report 2023-07-19 · accession 0001225208-23-007627 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-07-21 | 2023-07-19+ | CI | Neville Everett | EVP, Solutions, Corp Devt | M - OptEx | $212.91 | +14.2K | 15.6K | +1,039% | +$3.02M |
| D | 2023-07-21 | 2023-07-19 | CI | Neville Everett | EVP, Solutions, Corp Devt | S - Sale+OE | $295.21 | -13.2K | 4,937 | -73% | -$3.88M |
| DM | 2023-07-21 | 2023-07-19+ | CI | Neville Everett | EVP, Solutions, Corp Devt | M - OptEx | $0.00 | -14.2K | 4,474 | -76% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, $.01 Par Value | 2023-07-20 | M | A | 219 | $227.02 | 5,987 | D | — | — | |
| 2 | Common | Common Stock, $.01 Par Value | 2023-07-20 | M | A | 261 | $192.02 | 5,768 | D | — | — | |
| 3 | Common | Common Stock, $.01 Par Value | 2023-07-20 | M | A | 570 | $213.80 | 5,507 | D | — | — | |
| 4 | Common | Common Stock, $.01 Par Value | 2023-07-19 | S | D | 13,157 | $295.21 | 4,937 | D | — | — | |
| 5 | Common | Common Stock, $.01 Par Value | 2023-07-19 | M | A | 2,519 | $192.02 | 18,094 | D | — | — | |
| 6 | Common | Common Stock, $.01 Par Value | 2023-07-19 | M | A | 7,236 | $213.80 | 12,173 | D | — | — | |
| 7 | Common | Common Stock, $.01 Par Value | 2023-07-19 | M | A | 3,402 | $227.02 | 15,575 | D | — | — | |
| 8 | Derivative | Employee Stock Option (Right to Buy) | 2023-07-20 | M | D | 261 | $0.00 | 0 | D | $192.02 · 2021-02-26 to 2030-02-26 | 261 Common Stock, $.01 Par Value | (F2) This option was granted on February 26, 2020. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. |
| 9 | Derivative | Employee Stock Option (Right to Buy) | 2023-07-19 | M | D | 3,402 | $0.00 | 7,463 | D | $227.02 · 2023-03-01 to 2032-02-23 | 3,402 Common Stock, $.01 Par Value | (F4) This option was granted on February 23, 2022, and vests in three equal annual installments. The first installment became exercisable on March 1, 2023, and the next two installments become exercisable on March 1, 2024 and March 1, 2025. |
| 10 | Derivative | Employee Stock Option (Right to Buy) | 2023-07-19 | M | D | 2,519 | $0.00 | 261 | D | $192.02 · 2021-02-26 to 2030-02-26 | 2,519 Common Stock, $.01 Par Value | (F2) This option was granted on February 26, 2020. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. |
| 11 | Derivative | Employee Stock Option (Right to Buy) | 2023-07-20 | M | D | 219 | $0.00 | 7,244 | D | $227.02 · 2023-03-01 to 2032-02-23 | 219 Common Stock, $.01 Par Value | (F4) This option was granted on February 23, 2022, and vests in three equal annual installments. The first installment became exercisable on March 1, 2023, and the next two installments become exercisable on March 1, 2024 and March 1, 2025. |
| 12 | Derivative | Employee Stock Option (Right to Buy) | 2023-07-20 | M | D | 570 | $0.00 | 3,904 | D | $213.80 · 2022-03-01 to 2031-02-24 | 570 Common Stock, $.01 Par Value | (F3) This option was granted on February 24, 2021 and vests in three equal annual installments. The first two installments became exercisable on March 1, 2022 and March 1, 2023, and the last installment becomes exercisable on March 1, 2024. |
| 13 | Derivative | Employee Stock Option (Right to Buy) | 2023-07-19 | M | D | 7,236 | $0.00 | 4,474 | D | $213.80 · 2022-03-01 to 2031-02-24 | 7,236 Common Stock, $.01 Par Value | (F3) This option was granted on February 24, 2021 and vests in three equal annual installments. The first two installments became exercisable on March 1, 2022 and March 1, 2023, and the last installment becomes exercisable on March 1, 2024. |